Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ESPR Esperion Therapeutics	$1.17 -5.6%	$1.03	$0.69 ▼ $3.94	$231.89M	0.7	4.69 million shs	2.93 million shs
NAGE Niagen Bioscience	$10.16 -1.8%	$12.03	$2.53 ▼ $14.69	$800.70M	2.14	1.07 million shs	1.22 million shs
ORIC Oric Pharmaceuticals	$11.01 -1.2%	$8.82	$3.90 ▼ $14.67	$938.32M	1.54	784,173 shs	480,474 shs
ZYME Zymeworks	$14.25 -1.6%	$12.46	$9.03 ▼ $17.70	$992.98M	1.19	577,775 shs	431,049 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ESPR Esperion Therapeutics	0.00%	-1.68%	+6.36%	+23.16%	-55.34%
NAGE Niagen Bioscience	0.00%	-10.09%	-26.27%	+50.30%	+289.27%
ORIC Oric Pharmaceuticals	0.00%	-0.81%	+19.41%	+130.82%	+7.73%
ZYME Zymeworks	0.00%	+6.82%	+12.83%	+23.59%	+40.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ESPR Esperion Therapeutics	3.9189 of 5 stars	3.4	2.0	3.9	2.2	1.7	0.6
NAGE Niagen Bioscience	1.453 of 5 stars	3.5	0.0	0.0	2.5	0.0	0.0
ORIC Oric Pharmaceuticals	4.5539 of 5 stars	4.5	1.0	4.4	2.1	3.3	0.6
ZYME Zymeworks	3.1544 of 5 stars	3.5	4.0	0.0	2.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	498.29% Upside
NAGE Niagen Bioscience	3.00	Buy	$13.22	30.12% Upside
ORIC Oric Pharmaceuticals	3.00	Buy	$18.57	68.68% Upside
ZYME Zymeworks	2.90	Moderate Buy	$21.00	47.37% Upside

Current Analyst Ratings Breakdown

Latest ESPR, ZYME, ORIC, and NAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	ORIC Oric Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
7/3/2025	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$13.00
6/23/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/10/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $16.00
6/6/2025	NAGE Niagen Bioscience	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $23.00
5/29/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
5/27/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$13.00
5/20/2025	ZYME Zymeworks	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/20/2025	ZYME Zymeworks	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ESPR Esperion Therapeutics	$332.31M	0.70	$0.02 per share	48.70	($1.97) per share	-0.59
NAGE Niagen Bioscience	$99.60M	8.04	$0.06 per share	171.85	$0.60 per share	16.93
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.45 per share	N/A
ZYME Zymeworks	$93.38M	10.63	N/A	N/A	$6.63 per share	2.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
NAGE Niagen Bioscience	$8.55M	$0.17	59.76	∞	N/A	13.07%	19.06%	12.20%	N/A
ORIC Oric Pharmaceuticals	-$127.85M	-$1.87	N/A	N/A	N/A	N/A	-51.14%	-46.29%	8/11/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$1.49	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	7/30/2025 (Estimated)

Latest ESPR, ZYME, ORIC, and NAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ESPR Esperion Therapeutics	-$0.17	N/A	N/A	N/A	$62.55 million	N/A
8/11/2025	Q2 2025	ORIC Oric Pharmaceuticals	-$0.46	N/A	N/A	N/A	N/A	N/A
8/7/2025	N/A	ZYME Zymeworks	-$0.52	N/A	N/A	N/A	$17.18 million	N/A
5/8/2025	N/A	ZYME Zymeworks	-$0.45	-$0.30	+$0.15	N/A	$20.65 million	$27.11 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million
5/5/2025	Q1 2025	ORIC Oric Pharmaceuticals	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ESPR Esperion Therapeutics	N/A	1.18	0.81
NAGE Niagen Bioscience	N/A	3.66	3.12
ORIC Oric Pharmaceuticals	N/A	12.00	12.00
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ESPR Esperion Therapeutics	47.39%
NAGE Niagen Bioscience	15.41%
ORIC Oric Pharmaceuticals	95.05%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
ESPR Esperion Therapeutics	1.70%
NAGE Niagen Bioscience	9.39%
ORIC Oric Pharmaceuticals	6.82%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
NAGE Niagen Bioscience	120	78.77 million	71.37 million	N/A
ORIC Oric Pharmaceuticals	80	85.22 million	79.41 million	Optionable
ZYME Zymeworks	460	69.68 million	67.56 million	Optionable

ESPR, ZYME, ORIC, and NAGE Headlines

Recent News About These Companies

Zymeworks Inc. (NYSE:ZYME) Receives $21.00 Average Price Target from Analysts

July 19 at 2:29 AM | americanbankingnews.com

Zymeworks (NYSE:ZYME) Trading 7% Higher - Should You Buy?

July 18 at 6:15 PM | marketbeat.com

Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?

July 18 at 11:00 AM | zacks.com

Zymeworks Inc. to Release Second Quarter 2025 Financial Results on August 7, 2025

July 17 at 6:36 AM | quiverquant.comQ

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

July 17 at 6:36 AM | financialpost.comF

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

July 17 at 6:36 AM | financialpost.comF

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

July 17 at 6:00 AM | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 16, 2025 | marketbeat.com

ZYME | Zymeworks Inc. Annual Cash Flow Statement | MarketWatch

July 11, 2025 | marketwatch.com

Bispecific Antibody Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

July 9, 2025 | finance.yahoo.com

Zymeworks (NYSE:ZYME) Given "Neutral" Rating at HC Wainwright

July 3, 2025 | marketbeat.com

Zymeworks Amends Warrant Agreement with EcoR1 Capital

June 27, 2025 | tipranks.com

ZYME - Zymeworks Inc Registered Shs Dividends - Morningstar

June 27, 2025 | morningstar.comM

Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth

June 25, 2025 | finance.yahoo.com

Zymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by Brokerages

June 21, 2025 | marketbeat.com

All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy

June 20, 2025 | zacks.com

Rhumbline Advisers Has $985,000 Stock Position in Zymeworks Inc. (NYSE:ZYME)

June 20, 2025 | marketbeat.com

Zymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500

June 18, 2025 | kalkinemedia.comK

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

June 12, 2025 | seekingalpha.com

Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?

June 4, 2025 | zacks.com

Zymeworks’ zanidatamab gains approval in China for biliary tract cancer

June 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
The Meteoric Rise of Rocket Lab: A Space Stock to Watch
By Ryan Hasson | July 11, 2025
View The Meteoric Rise of Rocket Lab: A Space Stock to Watch
Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
3 Infrastructure Stocks Riding the U.S. Building Boom
By Chris Markoch | July 14, 2025
View 3 Infrastructure Stocks Riding the U.S. Building Boom
PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?
By Thomas Hughes | July 19, 2025
View PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?

ESPR, ZYME, ORIC, and NAGE Company Descriptions

Esperion Therapeutics NASDAQ:ESPR

$1.17 -0.07 (-5.65%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.17 0.00 (0.00%)

As of 07/18/2025 06:56 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Niagen Bioscience NASDAQ:NAGE

$10.16 -0.19 (-1.84%)

As of 07/18/2025 04:00 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Oric Pharmaceuticals NASDAQ:ORIC

$11.01 -0.13 (-1.17%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$11.02 +0.01 (+0.05%)

As of 07/18/2025 07:09 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Zymeworks NYSE:ZYME

$14.25 -0.23 (-1.59%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$14.26 +0.01 (+0.04%)

As of 07/18/2025 05:23 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time